Trials / Active Not Recruiting
Active Not RecruitingNCT04318938
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, randomized, open-label, multicenter phase II study investigating the advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping
Detailed description
The aim of this study is to compare efficacy of brigatinib and other 2nd-generation ALK tyrosin kinase inhibitor (TKI) in 1st and 2nd line treatment and to explore resistance patterns according to treatment and molecular properties of the tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brigatinib | Treatment with Brigatinib |
| DRUG | Tyrosine kinase inhibitor | Treatment with any TKI |
Timeline
- Start date
- 2020-03-30
- Primary completion
- 2026-04-30
- Completion
- 2026-04-30
- First posted
- 2020-03-24
- Last updated
- 2026-03-02
Locations
26 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT04318938. Inclusion in this directory is not an endorsement.